| http://www.w3.org/ns/prov#value | - In 2011, Genzyme expects growth in this business to be driven primarily by Mozobil, Thymoglobulin?? (anti-thymocyte globulin (rabbit)) and Clolar through increased penetration in key segments of the U.S. and mature European markets, and expansion in emerging markets such as China.
|
